The effects of fish oil omega-3 fatty acid supplementation on mental health parameters and metabolic status of patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial

Objective This study was conducted to evaluate the effects of fish oil omega-3 fatty acid supplementation on mental health parameters and metabolic status of women with polycystic ovary syndrome (PCOS). Methods This randomized double-blind, placebo-controlled trial was conducted on 60 women with PCO...

Full description

Saved in:
Bibliographic Details
Main Authors: Mehrdad Amini (Author), Fereshteh Bahmani (Author), Fatemeh Foroozanfard (Author), Zahra Vahedpoor (Author), Amir Ghaderi (Author), Mohsen Taghizadeh (Author), Hassan Karbassizadeh (Author), Zatollah Asemi (Author)
Format: Book
Published: Taylor & Francis Group, 2020-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective This study was conducted to evaluate the effects of fish oil omega-3 fatty acid supplementation on mental health parameters and metabolic status of women with polycystic ovary syndrome (PCOS). Methods This randomized double-blind, placebo-controlled trial was conducted on 60 women with PCOS, aged 18-40 years old. Participants were randomly assigned into two groups to receive either 2 × 1000 mg/day fish oil omega-3 fatty acid (n = 30) or placebo (n = 30) after lunch for 12 weeks. Metabolic profiles were quantified at baseline and after the 12-week intervention. Results Compared with the placebo, omega-3 fatty acid intake led to a significant improvement in Beck Depression Inventory [β (difference in the mean outcomes measures between treatment groups after intervention) -1.05; 95% CI: -1.84, -0.26; p = .01], general health questionnaire (β -1.68; 95% CI: -3.12, -0.24; p = .02) and depression anxiety and stress scale (β -2.03; 95% CI: -3.60, -0.46; p = .01). Omega-3 fatty acid supplementation significantly decreased serum insulin levels (β -2.09 µIU/mL; 95% CI: -3.77, -0.41; p = .01), homeostasis model of assessment-insulin resistance (β -0.74; 95% CI: -1.13, -0.34; p < .001), total testosterone (β -0.23 ng/mL; 95% CI: -0.39, -0.06; p = .03) and hirsutism (β -0.75; 95% CI: -1.17, -0.33; p = .001), and significantly increased the quantitative insulin sensitivity check index (β 0.01; 95% CI: 0.003, 0.02; p = .008) compared with the placebo. Additionally, omega-3 fatty acid intake resulted in a significant decrease in high sensitivity C-reactive protein (β -1.46 mg/L; 95% CI: -2.16, -0.75; p < .001) and malondialdehyde (β -0.28 µmol/L; 95% CI: -0.52, -0.05; p = .03); also significant rises in plasma total glutathione (β 59.09 µmol/L; 95% CI: 7.07, 111.11; p = .02) was observed compared with the placebo. Omega-3 fatty acid supplementation did not change other metabolic parameters. Conclusion Overall, omega-3 fatty acid supplementation for 12 weeks to patients with PCOS had beneficial effects on mental health parameters, insulin metabolism, total testosterone, hirsutism and few inflammatory markers and oxidative stress.
Item Description:0167-482X
1743-8942
10.1080/0167482X.2018.1508282